Ask the Experts: Cardiology

Q&A begins
    • Cardiovascular Disease
    • Professor of Medicine and Director, UCLA-Barbra Streisand Women’s Heart Health Program at UCLA

    Karol E. Watson, MD, PhD, FACC, is Director of the UCLA Barbra Streisand Women’s Heart Health Program, Codirector of the UCLA Program in Preventive Cardiology, and Director of the UCLA Cardiology Fellowship.  She was a coauthor of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Dr. Watson is a past Vice President for the Association of Black Cardiologists, an American Society of Hypertension Specialist in Hypertension, a founding board member and fellow of the National Lipid Association, and a member of the national advisory board for WomenHeart. Dr. Watson has authored more than 100 publications addressing subjects including heart disease prevention, vascular calcification, hypertension, hypercholesterolemia, and cardiovascular disease in black Americans. Dr. Watson has been writing for NEJM Journal Watch Cardiology since 2015.

    • Clinical Cardiac Electrophysiology
    • Professor of Medicine and Director of Cardiac Electrophysiology at UT Southwestern Medical Center at Dallas

    Mark S. Link, MD, is Professor of Medicine and Director of Cardiac Electrophysiology at UT Southwestern Medical Center in Dallas. As a practicing cardiac electrophysiologist, Dr. Link has clinical interests in ablation procedures and sudden cardiac death. His active research projects focus on sudden cardiac death in athletes, commotio cordis, long-term follow-up of patients with ICDs, and the influence of air pollution on sudden cardiac death and arrhythmias. Dr. Link is currently an Associate Editor at Circulation and a member of the editorial boards of EP Lab Digest, Heart Rhythm, and UpToDate. He serves on the American Heart Association (AHA) Emergency Care Committee, and he is immediate past chair of the AHA Science subcommittee of the AHA Emergency Care Committee. He has been Associate Editor of NEJM Journal Watch Cardiology since 2007 and Deputy Editor since 2015.

    • Cardiovascular Disease
    • Clinical research,epidemiology, clinical trials design and implementation,Statistics
    Vice Chair Research, Department of Medicine, University of Toronto
    Vice Chair Research, Department of Medicine, University of Toronto

    Dr. Farkouh is the Peter Munk Chair in Multinational Clinical Trials at the Peter Munk Cardiac Centre, Director of the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, Professor and Vice-Chair, Research, Department of Medicine at the University of Toronto. He is a graduate of the Schulich School of Medicine at Western University. Dr. Farkouh completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of Medicine at Mount Sinai New York respectively and holds an MSc in Clinical Epidemiology from McMaster University. Prior to his current appointments, he served as the founding director of the Mount Sinai Cardiovascular Clinical Trials Unit in New York City. Dr. Farkouh is internationally known for his work on the management of acute coronary syndromes in the emergency room. He has a special interest and expertise in the field of cardiovascular disease in diabetic patients. He is currently the project officer for numerous clinical trials on questions related to diabetes and heart disease including the NIH-sponsored FREEDOM trial. He chairs the committee on diabetes and heart disease at the Banting and Best Centre and at the University of Toronto. Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the Year at the Mayo Clinic, and was awarded the Jan J. Kellermann Memorial Award for Cardiovascular Disease Prevention from the International Academy of Cardiology. Dr. Farkouh serves as Section Editor for Diabetes and Metabolism at the Journal of the American College of Cardiology. 

  • Dr. Timothy D. Henry is the Medical Director of The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital in Cincinnati, Ohio. Prior to The Lindner Research Center, he was the Chief of Cardiology at the Smidt Heart Institute at Cedars Sinai Medical Center and a Professor of Medicine at Cedars-Sinai and UCLA, the Director of Research at the Minneapolis Heart Institute Foundation, at Abbott Northwestern Hospital in Minneapolis and prior to that Director of Interventional Cardiology and the Cardiac Cath Lab at Hennepin County Medical Center. 

    He has published over 450 manuscripts and book chapters and has served on the Emergency Care Committee for the ACC, the AHA Mission: Lifeline Advisory Committee, the AHA Acute Cardiac Care Committee, ACC Interventional Subcommittee, and the Executive Committee for the Society for Cardiovascular Angiography and Interventions. His research interests include interventional cardiology, acute myocardial infarction, and novel therapies, including stem cell and gene therapy, for refractory angina patients who are not candidates for standard revascularization techniques.

    He has served as principal investigator and steering committees of multiple large, multicenter research trials in acute myocardial infarction and refractory angina. He is principal investigator for 1 of 7 NIH Clinical Cardiovascular Stem Cell Centers and has one of the largest research programs in the world for cardiovascular stem cell therapy. Among other awards, Henry has been named to the Best Doctors in America list each year between 2007 and 2019, became a Master Fellow for the Society for Cardiovascular Angioplasty and Interventions in 2015, received the American Heart Association’s Heart and Stroke Hero Award in Research in 2013 and was granted the LUMEN Global Lifetime Achievement Award in MI in 2012.

    • Interventional Cardiology
    • Interventional Cardiologist at Kaiser Permanente

    Tim Dewhurst MD FACC is an interventional cardiologist at Kaiser Permanente in Washington state, based in Seattle. He did his undergraduate degree at Stanford, returning home to the University of Alberta for his medical degree. Post graduate training was in internal medicine at Emory and both general  and interventional cardiology fellowships at the University of Washington. He then joined a fee for service multispecialty group where he focused on clinical care and clinical research. He actively participated in clinical operational and quality leadership as well as serving on the medical group’s board of directors and chairing both the compensation committee and the hospital quality peer review committee. 

    In 2011 he changed gears and joined an integrated health system. He continued clinical  practice and subsequently led the state chapter of the American College of Cardiology. 

    He is actively involved in national health care quality measures both with the ACC and the National Quality Forum. He is also the Medical Director for Clinical Value Improvement at Washington Permanente Medical Group and serves on the group’s finance committee. In this role he engages in peer to peer discussion about reducing low value care and how to recover the joy of medicine by engaging patients in their care and shared decision making.

    • Cardiovascular Disease
    • Clinical Cardiac Electrophysiology
    • Internal Medicine
    • Physician at Massachusetts General Hospital and Harvard Medical School

    William Hucker, MD, PhD is a cardiac electrophysiologist and physician scientist at Massachusetts General Hospital in Boston, MA. His clinical interests include ablation procedures for atrial and ventricular arrhythmias, as well as device therapy for arrhythmias and heart failure. His research interests include mechanisms of atrial fibrillation, arrhythmia models, and arrhythmia mapping systems. Dr. Hucker has served as a member of the American College of Cardiology Task Force on Expert Consensus Decision Pathways and was a coauthor for ACC Expert Consensus Decision Pathways for both Periprocedural Anticoagulation Management as well as Management of Bleeding in Patients on Oral Anticoagulants in 2017.